EUCTR2005-003216-30-IT进行中（未招募）不适用
Prospective, multicenter, randomized, parallel-group, open-label phase II study to investigate the efficacy, safety and tolerability of 2 doses of ZK 219477 16 and 12 mg/m2 body surface area in patients with metastatic breast cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- SCHERING
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Prospective, multicenter, randomized, parallel-group, open-label phase II study to investigate the efficacy, safety and tolerability of 2 doses of ZK 219477 (16 and 12 mg/m² body surface area) in patients with metastatic breast cancerHistologically proven metastatic breast cancer.EUCTR2005-003216-30-GBBayer Schering Pharma AG
进行中（未招募）
不适用
Prospective, multicenter, randomized, parallel-group, open-label phase II study to investigate the efficacy, safety and tolerability of 2 doses of ZK 219477 (16 and 12 mg/m2 body surface area) in patients with metastatic breast cancerHistologically proven metastatic breast cancer.EUCTR2005-003216-30-ATSchering AG54
进行中（未招募）
不适用
Prospective, multicenter, randomized, parallel-group, open-label phase II study to investigate the efficacy, safety and tolerability of 2 doses of ZK 219477 (16 and 12 mg/m2 body surface area) in patients with metastatic breast cancerHistologically proven metastatic breast cancer.EUCTR2005-003216-30-SISchering AG54
Unknown
3 期
A comparative study to determine the efficacy and safety of Brinzolamide 1% ophthalmic suspension of Cipla Ltd., India against Azopt® of Alcon Pharma Ltd., US in subjects with chronic open angle glaucoma or ocular hypertension.CTRI/2015/05/005760Cipla Ltd
进行中（未招募）
1 期
DEFIBROTIDE AS PREVENTION AND TREATMENT OF RESPIRATORY DISTRESS AND CYTOKINE RELEASE SYNDROME OF COVID-19COVID-19EUCTR2020-001409-21-ESFFIS120